184 related articles for article (PubMed ID: 25976768)
21. Limited Clinical Significance of Dimeric Form of Pyruvate Kinase as a Diagnostic and Prognostic Biomarker in Non-small Cell Lung Cancer.
Rzechonek A; Kaminska A; Mamczur P; Drapiewski A; Budzynski W
Adv Exp Med Biol; 2017; 955():51-57. PubMed ID: 27683215
[TBL] [Abstract][Full Text] [Related]
22. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
Han B; Guo Z; Ma Y; Kang S; Wang Y; Wei Q; Wu X
Int J Clin Exp Pathol; 2015; 8(4):4113-9. PubMed ID: 26097600
[TBL] [Abstract][Full Text] [Related]
23. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer.
Kawai O; Ishii G; Kubota K; Murata Y; Naito Y; Mizuno T; Aokage K; Saijo N; Nishiwaki Y; Gemma A; Kudoh S; Ochiai A
Cancer; 2008 Sep; 113(6):1387-95. PubMed ID: 18671239
[TBL] [Abstract][Full Text] [Related]
24. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
[TBL] [Abstract][Full Text] [Related]
26. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
27. Predictive role of CEA and CYFRA 21-1 in patients with advanced-stage NSCLC treated with erlotinib.
Fiala O; Pesek M; Finek J; Benesova L; Minarik M; Bortlicek Z; Topolcan O
Anticancer Res; 2014 Jun; 34(6):3205-10. PubMed ID: 24922695
[TBL] [Abstract][Full Text] [Related]
28. The value of serum Bcl-2 levels in advanced lung cancer patients.
Tas F; Duranyildiz D; Oguz H; Camlica H; Oral EN; Yasasever V; Topuz E
Med Oncol; 2005; 22(2):139-43. PubMed ID: 15965276
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer.
Laudanski J; Burzykowski T; Niklinska W; Chyczewski K; Furman M; Niklinski J
Lung Cancer; 1998 Dec; 22(3):191-200. PubMed ID: 10048472
[TBL] [Abstract][Full Text] [Related]
30. Expressions of insulin-like growth factor receptor-1 and insulin-like growth factor binding protein 3 in advanced non-small-cell lung cancer.
Kim YH; Sumiyoshi S; Hashimoto S; Masago K; Togashi Y; Sakamori Y; Okuda C; Mio T; Mishima M
Clin Lung Cancer; 2012 Sep; 13(5):385-90. PubMed ID: 22285568
[TBL] [Abstract][Full Text] [Related]
31. Granulocyte colony stimulating factor (G-CSF) and macrophage colony stimulating factor (M-CSF) as potential tumor markers in non small cell lung cancer diagnosis.
Bahar B; Acedil Ayc Iota B; Çoşkun U; Büyükberber S; Benekli M; Yildiz R
Asian Pac J Cancer Prev; 2010; 11(3):709-12. PubMed ID: 21039040
[TBL] [Abstract][Full Text] [Related]
32. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
33. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
34. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
[TBL] [Abstract][Full Text] [Related]
35. Prognostic role of serum cytokeratin 19 fragments in advanced non-small-cell lung cancer: association of marker changes after two chemotherapy cycles with different measures of clinical response and survival.
Nisman B; Biran H; Heching N; Barak V; Ramu N; Nemirovsky I; Peretz T
Br J Cancer; 2008 Jan; 98(1):77-9. PubMed ID: 18087272
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
37. Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Kawaishi M; Fujiwara Y; Fukui T; Kato T; Yamada K; Ohe Y; Kunitoh H; Sekine I; Yamamoto N; Nokihara H; Watabe T; Shimoda Y; Arao T; Nishio K; Tamura T; Koizumi F
J Thorac Oncol; 2009 Feb; 4(2):208-13. PubMed ID: 19179898
[TBL] [Abstract][Full Text] [Related]
38. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
[TBL] [Abstract][Full Text] [Related]
39. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
[TBL] [Abstract][Full Text] [Related]
40. Glycosylated Alpha-1-acid glycoprotein 1 as a potential lung cancer serum biomarker.
Ayyub A; Saleem M; Fatima I; Tariq A; Hashmi N; Musharraf SG
Int J Biochem Cell Biol; 2016 Jan; 70():68-75. PubMed ID: 26563422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]